Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.4K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

208
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pheochromocytoma with sympathetic hyperactivity: a diagnostic challenge.

Revista espanola de medicina nuclear e imagen molecular·2026
Same author

Treatment with radionuclide-labeled peptides in refractory meningiomas: Updated review and clinical perspectives.

Revista espanola de medicina nuclear e imagen molecular·2025
Same author

Update on iodine-refractory differentiated thyroid carcinoma.

Revista espanola de medicina nuclear e imagen molecular·2023
Same author

Incidental finding of epiploic appendagitis in the <sup>18</sup>F-FDG PET/CT study of a patient with recurrence of ovarian cancer.

Revista espanola de medicina nuclear e imagen molecular·2023
Same author

<sup>18</sup>F-FDG PET/CT role in Pott disease.

Revista espanola de medicina nuclear e imagen molecular·2022
Same author

Bilateral adrenal hypermetabolism with <sup>18</sup>F-FDG PET/CT as an incidental finding in suspected recurrence of adrenocortical carcinoma.

Revista espanola de medicina nuclear e imagen molecular·2021
Same journal

Integration of Nuclear Medicine in Multidisciplinary Committees: Involvement, perception, and areas for improvement. Results of a national survey.

Revista espanola de medicina nuclear e imagen molecular·2026
Same journal

Prediction of PD-L1 expression in gastric cancer using <sup>18</sup>F-FDG PET/CT radiomics.

Revista espanola de medicina nuclear e imagen molecular·2026
Same journal

Bilateral renoureteral plasmacytoma. An unusual presentation in a young patient with multiple myeloma.

Revista espanola de medicina nuclear e imagen molecular·2026
Same journal

The nuclear oncologist.

Revista espanola de medicina nuclear e imagen molecular·2026
Same journal

Prognostic value of radionics based on <sup>18</sup>F-FDG PET/CT in Hodgkin lymphoma: A systematic review.

Revista espanola de medicina nuclear e imagen molecular·2026
Same journal

Cardiac amyloidosis: An update on nuclear cardiology in diagnosis and follow-up.

Revista espanola de medicina nuclear e imagen molecular·2026
See all related articles

Related Experiment Video

Updated: Aug 8, 2025

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

18.4K

18F-DCFPyL PET/CT guidelines.

A L Gutiérrez Cardo1, J A Vallejo Casas2, J R García Garzón3

  • 1Servicio de Medicina Nuclear, Hospital Regional de Málaga, Málaga, Spain.

Revista Espanola De Medicina Nuclear E Imagen Molecular
|March 6, 2023
PubMed
Summary
This summary is machine-generated.

This guide offers nuclear medicine physicians evidence-based recommendations for performing 18F-DCFPyL PET/CT scans safely and efficiently in prostate cancer patients with PSMA overexpression. It covers image interpretation and reporting using PROMISE and PSMA-RADS criteria.

Keywords:
Cáncer de próstataDCFPyLGuidelinesGuíaPET/CTPET/TCProstate cancer

More Related Videos

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT
10:53

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Published on: November 23, 2012

19.2K
Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

14.0K

Related Experiment Videos

Last Updated: Aug 8, 2025

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

18.4K
Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT
10:53

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Published on: November 23, 2012

19.2K
Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

14.0K

Area of Science:

  • Nuclear Medicine
  • Radiology
  • Oncology

Background:

  • Prostate cancer management requires accurate staging and restaging.
  • Positron Emission Tomography/Computed Tomography (PET/CT) with PSMA-targeted tracers like 18F-DCFPyL offers improved detection of prostate-specific membrane antigen (PSMA) overexpression.

Purpose of the Study:

  • To provide nuclear medicine physicians with an expert-consensus, evidence-based guide for performing 18F-DCFPyL PET/CT procedures.
  • To establish recommendations for safe and efficient 18F-DCFPyL PET/CT in prostate cancer patients.
  • To standardize image interpretation and reporting for improved clinical utility.

Main Methods:

  • Development of consensus-based recommendations by experts in nuclear medicine and oncology.
  • Review of scientific evidence regarding 18F-DCFPyL PET/CT acquisition, reconstruction, and interpretation.
  • Inclusion of guidelines for analyzing false positives and reporting findings.

Main Results:

  • Detailed recommendations for 18F-DCFPyL PET/CT examination, including reconstruction parameters and image presentation.
  • Analysis of potential false positives, their interpretation, and strategies for avoidance.
  • Emphasis on structured reporting using PROMISE criteria and PSMA-RADS classification.

Conclusions:

  • This guide serves as a crucial tool for nuclear medicine physicians performing 18F-DCFPyL PET/CT.
  • Standardized procedures and reporting enhance the safety, efficiency, and diagnostic accuracy of the examination.
  • Adherence to PROMISE criteria and PSMA-RADS promotes consistent and clinically relevant reporting for prostate cancer management.